Agilent Technologies recently introduced the SureSelect Cancer Research Pan Heme, a hybrid capture NGS panel that integrates DNA and RNA profiling, automation and bioinformatics to study 359 DNA genes and 124 RNA genes in hematologic malignancy research. The new panel, codeveloped with Roswell Park Comprehensive Cancer Center and designed for a roughly 48 hour sample to report workflow, deepens Agilent Technologies' focus on comprehensive, workflow based cancer research solutions rather than...
Agilent Technologies (NYSE:A) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.8%. Currently, Agilent Technologies has a market capitalization
Tipranks Press Release.
Detailed price information for Agilent Technologies (A-N) from The Globe and Mail including charting and trades.
Agilent (A) to acquire Proscia for up to $270M to expand AI-powered digital pathology & diagnostic capabilities. Stock edges higher.
This is the newest page. Registered accounts read further back.